NCT01966367View on ClinicalTrials.gov

CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

February 28, 2030

Study Completion Date

February 28, 2030

Conditions
Bone Marrow Failure SyndromeSevere Aplastic AnemiaSevere Congenital NeutropeniaAmegakaryocytic ThrombocytopeniaDiamond-Blackfan AnemiaSchwachman Diamond SyndromePrimary Immunodeficiency SyndromesAcquired Immunodeficiency SyndromesHistiocytic SyndromeFamilial Hemophagocytic LymphocytosisLymphohistiocytosisMacrophage Activation SyndromeLangerhans Cell Histiocytosis (LCH)HemoglobinopathiesSickle Cell DiseaseSickle Cell-beta-thalassemia
Interventions
BIOLOGICAL

CD34 Stem Cell Selection Therapy

The CliniMACS (PLUS) Reagent System (Miltenyi CliniMACS CD34+ Cell Selection Device) will be used to remove T-cells from the peripheral blood stem cell transplant in order to decrease the risk of acute and chronic graft versus host disease (GVHD).

Trial Locations (1)

10032

Morgan Stanley Children's Hospital, New York-Presbyterian, Columbia University, New York

All Listed Sponsors
lead

Diane George

OTHER

NCT01966367 - CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter